Dr Kate Liddiard
Research Associate
- liddiardk@cardiff.ac.uk
- 2F.12, Cancer Genetics Building, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
Overview
I am a post-doctoral researcher within the telomere research group headed by Prof Duncan Baird. I am interested in the mechanisms and consequences of DNA damage and telomere fusion in the context of malignant transformation and clonal evolution.
Biography
Publications
2022
- Liddiard, K., Aston-Evans, A. N., Cleal, K., Hendrickson, E. A. and Baird, D. M. 2022. POLQ suppresses genome instability and alterations in DNA repeat tract lengths. NAR Cancer 4(3), article number: zcac020. (10.1093/narcan/zcac020)
2021
- Liddiard, K., Grimstead, J., Cleal, K., Evans, A. and Baird, D. 2021. Tracking telomere fusions through crisis reveals conflict between DNA transcription and the DNA Damage Response. NAR Cancer 3(1), article number: zcaa044. (10.1093/narcan/zcaa044)
2019
- Escudero, L., Cleal, K., Ashelford, K., Fegan, C., Pepper, C., Liddiard, K. and Baird, D. M. 2019. Telomere fusions associate with coding sequence and copy number alterations in CLL. Leukemia 33, pp. 2093-2097. (10.1038/s41375-019-0423-y)
- Liddiard, K., Ruis, B., Kan, Y., Cleal, K., Ashelford, K. E., Hendrickson, E. A. and Baird, D. M. 2019. DNA Ligase 1 is an essential mediator of sister chromatid telomere fusions in G2 cell cycle phase. Nucleic Acids Research 47(5), pp. 2402-2424. (10.1093/nar/gky1279)
2016
- Liddiard, K., Ruis, B., Takasugi, T., Harvey, A., Ashelford, K. E., Hendrickson, E. A. and Baird, D. M. 2016. Sister chromatid telomere fusions, but not NHEJ-mediated inter-chromosomal telomere fusions, occur independently of DNA ligases 3 and 4. Genome Research 26, pp. 588-600. (10.1101/gr.200840.115)
2015
- Liddiard, K. and Taylor, P. R. 2015. Understanding local macrophage phenotypes in disease: shape-shifting macrophages. Nature Medicine 21(2), pp. 119-120. (10.1038/nm.3798)
2014
- Jones, R. E. et al. 2014. Escape from telomere-driven crisis is DNA Ligase III dependent. Cell Reports 8(4), pp. 1063-1076. (10.1016/j.celrep.2014.07.007)
2013
- Morgan, R. G., Pearn, L., Liddiard, K., Pumford, S. L., Burnett, A. K., Tonks, A. and Darley, R. L. 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27(2), pp. 336-343. (10.1038/leu.2012.221)
2012
- Liddiard, K., Burnett, A. K., Darley, R. L. and Tonks, A. 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26(1), pp. 177-179. (10.1038/leu.2011.188)
2011
- McDonald, J. U. et al. 2011. In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils. The FASEB Journal 25(6), pp. 1972-1982. (10.1096/fj.10-178517)
- Liddiard, K., Rosas, M., Davies, L. C., Jones, S. A. and Taylor, P. R. 2011. Macrophage heterogeneity and acute inflammation. European Journal of Immunology 41(9), pp. 2503-2508. (10.1002/eji.201141743)
2010
- Morgan, R. G., Pearn, L., Liddiard, K., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116(21), article number: 1573.
- Liddiard, K., Hills, R. K., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29(13), pp. 2005-2012. (10.1038/onc.2009.462)
2009
- Bee, T. et al. 2009. Alternative Runx1 promoter usage in mouse developmental hematopoiesis. Blood Cells, Molecules, and Diseases 43(1), pp. 35-42. (10.1016/j.bcmd.2009.03.011)
2008
- Rosas, M. et al. 2008. The induction of inflammation by dectin-1 in vivo is dependent on myeloid cell programming and the progression of phagocytosis. Journal of Immunology 181(5), pp. 3549-3557.